1. Pembrolizumab-associated sarcoidosis
Jonathan Cotliar, MD, Christiane Querfeld, MD, PhD, William J. Boswell, MD, Naveen Raja, DO, Dan Raz, MD, Robert Chen, MD 
JAAD Case Reports 
Volume 2, Issue 4, Pages (July 2016)
DOI: /j.jdcr
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Clinical presentation. A, Nontender subcutaneous nodule of right forearm without overlying erythema while taking pembrolizumab for refractory Hodgkin lymphoma. B, Resolution of right forearm subcutaneous nodule while not taking pembrolizumab during course of prednisone.
JAAD Case Reports 2016 2, DOI: ( /j.jdcr )
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Microscopic examination. A, Normal epidermis with mild perivascular lymphohistiocytic inflammation. B, Focal dermal epithelioid granuloma. (A and B, Hematoxylin-eosin stain; original magnifications: A, ×10; B, ×20.)
JAAD Case Reports 2016 2, DOI: ( /j.jdcr )
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Radiographic examination. Positron emission tomography while taking pembrolizumab shows uptake within left scapula (A), sternum, hilar/mediastinal lymph nodes (B). Resolution of left scapula lesion (C), sternal lesion, and adenopathy (D) while not taking pembrolizumab during prednisone course.
JAAD Case Reports 2016 2, DOI: ( /j.jdcr )
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions